89 related articles for article (PubMed ID: 23482636)
1. Sushi domain-containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase.
Holmquist E; Okroj M; Nodin B; Jirström K; Blom AM
FASEB J; 2013 Jun; 27(6):2355-66. PubMed ID: 23482636
[TBL] [Abstract][Full Text] [Related]
2. The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly.
Escudero-Esparza A; Kalchishkova N; Kurbasic E; Jiang WG; Blom AM
FASEB J; 2013 Dec; 27(12):5083-93. PubMed ID: 23964079
[TBL] [Abstract][Full Text] [Related]
3. The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients.
Englund E; Reitsma B; King BC; Escudero-Esparza A; Owen S; Orimo A; Okroj M; Anagnostaki L; Jiang WG; Jirström K; Blom AM
BMC Cancer; 2015 Oct; 15():737. PubMed ID: 26480818
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution and functional analysis of Sushi domain-containing protein 4.
Tu Z; Cohen M; Bu H; Lin F
Am J Pathol; 2010 May; 176(5):2378-84. PubMed ID: 20348246
[TBL] [Abstract][Full Text] [Related]
5. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
6. Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement.
Liszewski MK; Atkinson JP
J Immunol; 1996 Jun; 156(11):4415-21. PubMed ID: 8666815
[TBL] [Abstract][Full Text] [Related]
7. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
8. The role of complement inhibitors beyond controlling inflammation.
Blom AM
J Intern Med; 2017 Aug; 282(2):116-128. PubMed ID: 28345259
[TBL] [Abstract][Full Text] [Related]
9. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q.
Kang YS; Do Y; Lee HK; Park SH; Cheong C; Lynch RM; Loeffler JM; Steinman RM; Park CG
Cell; 2006 Apr; 125(1):47-58. PubMed ID: 16615889
[TBL] [Abstract][Full Text] [Related]
10. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
11. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
12. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
Sobel AT; Cooper NR; Schreiber RD
J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
[TBL] [Abstract][Full Text] [Related]
13. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
Kameyoshi Y; Matsushita M; Okada H
Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
[TBL] [Abstract][Full Text] [Related]
14. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
15. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.
Brown JS; Hussell T; Gilliland SM; Holden DW; Paton JC; Ehrenstein MR; Walport MJ; Botto M
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):16969-74. PubMed ID: 12477926
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells.
Duvall MR; Hwang HY; Boackle RJ
Immunobiology; 2010 May; 215(5):395-405. PubMed ID: 19586684
[TBL] [Abstract][Full Text] [Related]
17. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
[TBL] [Abstract][Full Text] [Related]
18. Complement inactivation by recombinant human C3 derivatives.
Kölln J; Spillner E; Andrä J; Klensang K; Bredehorst R
J Immunol; 2004 Nov; 173(9):5540-5. PubMed ID: 15494503
[TBL] [Abstract][Full Text] [Related]
19. Sushi domain-containing protein 4 controls synaptic plasticity and motor learning.
González-Calvo I; Iyer K; Carquin M; Khayachi A; Giuliani FA; Sigoillot SM; Vincent J; Séveno M; Veleanu M; Tahraoui S; Albert M; Vigy O; Bosso-Lefèvre C; Nadjar Y; Dumoulin A; Triller A; Bessereau JL; Rondi-Reig L; Isope P; Selimi F
Elife; 2021 Mar; 10():. PubMed ID: 33661101
[TBL] [Abstract][Full Text] [Related]
20. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway).
Thielens NM; Colomb MG
Eur J Immunol; 1986 Jun; 16(6):617-22. PubMed ID: 3487454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
